Inhibition of glycogen breakdown by imino sugars in vitro and in vivo - PubMed

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo

Ulrika Andersson et al. Biochem Pharmacol. 2004.

Abstract

The imino sugar N-butyldeoxynojirimycin (NB-DNJ) is a glucose analogue which inhibits the glycoprotein N-glycan processing enzymes alpha-glucosidases I and II and the ceramide glucosyltransferase that catalyses the first step of glycosphingolipid biosynthesis. This and other N-alkylated DNJ compounds have the potential to inhibit other glucosidase, including acid alpha-glucosidase and alpha-1,6-glucosidase, enzymes involved in glycogen breakdown. We have investigated the effect of NB-DNJ and N-nonyldeoxynojirimycin (NN-DNJ) on glycogen catabolism. Both NB-DNJ and NN-DNJ were potent inhibitors of acid alpha-glucosidase and alpha-1,6-glucosidase in vitro. NB-DNJ and NN-DNJ inhibited liver glycogen breakdown in vivo in fasting mice. Inhibition of glycogen catabolism occurred in the cytosol and lysosomes. The liver glycogen breakdown inhibition was only induced at high doses of NB-DNJ, whereas NN-DNJ caused glycogen accumulation at lower doses. The in vivo effect of NB-DNJ on liver glycogen was transient as there was no inhibition of breakdown after 90 days of treatment. The inhibition by NN-DNJ, was more pronounced, reached a plateau at 50 days and then remained unchanged. Increased glycogen was also observed in skeletal muscle in NB-DNJ- and NN-DNJ-treated mice. Since the effects on glycogen metabolism by NB-DNJ are transient and only occur at high concentrations, it is not predicted that glycogen breakdown will be impaired in patients receiving NB-DNJ therapy. NN-DNJ is the prototype of long alkyl chain derivatives of DNJ that are entering pre-clinical development as potential hepatitis B/hepatitis C (HBV/HCV) therapeutics. Depending on the dose of these compounds used, there is the potential for glycogen catabolism to be partially impaired in experimental animals and man.

Similar articles

• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.

  Andersson U, Butters TD, Dwek RA, Platt FM. Andersson U, et al. Biochem Pharmacol. 2000 Apr 1;59(7):821-9. doi: 10.1016/s0006-2952(99)00384-6. Biochem Pharmacol. 2000. PMID: 10718340

• Inhibition of α-glucosidase activity by N-deoxynojirimycin analogs in several insect phloem sap feeders.

  Ya'kobovitz MK, Butters TD, Cohen E. Ya'kobovitz MK, et al. Insect Sci. 2016 Feb;23(1):59-67. doi: 10.1111/1744-7917.12229. Epub 2015 Aug 18. Insect Sci. 2016. PMID: 25900765

• Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.

  Zitzmann N, Mehta AS, Carrouée S, Butters TD, Platt FM, McCauley J, Blumberg BS, Dwek RA, Block TM. Zitzmann N, et al. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11878-82. doi: 10.1073/pnas.96.21.11878. Proc Natl Acad Sci U S A. 1999. PMID: 10518544 Free PMC article.

• Substrate reduction therapy for glycosphingolipid storage disorders.

  Lachmann RH, Platt FM. Lachmann RH, et al. Expert Opin Investig Drugs. 2001 Mar;10(3):455-66. doi: 10.1517/13543784.10.3.455. Expert Opin Investig Drugs. 2001. PMID: 11227045 Review.

• 1-Deoxynojirimycin and its Derivatives: A Mini Review of the Literature.

  Wang H, Shen Y, Zhao L, Ye Y. Wang H, et al. Curr Med Chem. 2021;28(3):628-643. doi: 10.2174/0929867327666200114112728. Curr Med Chem. 2021. PMID: 31942844 Review.

Cited by

• Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.

  Steet R, Chung S, Lee WS, Pine CW, Do H, Kornfeld S. Steet R, et al. Biochem Pharmacol. 2007 May 1;73(9):1376-83. doi: 10.1016/j.bcp.2006.12.015. Epub 2006 Dec 15. Biochem Pharmacol. 2007. PMID: 17217920 Free PMC article.

• Pharmacological Chaperone Therapy for Pompe Disease.

  Borie-Guichot M, Tran ML, Génisson Y, Ballereau S, Dehoux C. Borie-Guichot M, et al. Molecules. 2021 Nov 29;26(23):7223. doi: 10.3390/molecules26237223. Molecules. 2021. PMID: 34885805 Free PMC article. Review.

• Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses.

  Chang J, Wang L, Ma D, Qu X, Guo H, Xu X, Mason PM, Bourne N, Moriarty R, Gu B, Guo JT, Block TM. Chang J, et al. Antimicrob Agents Chemother. 2009 Apr;53(4):1501-8. doi: 10.1128/AAC.01457-08. Epub 2009 Feb 17. Antimicrob Agents Chemother. 2009. PMID: 19223639 Free PMC article.

• Pharmacokinetics, Tissue Distribution, and Elimination of Three Active Alkaloids in Rats after Oral Administration of the Effective Fraction of Alkaloids from Ramulus Mori, an Innovative Hypoglycemic Agent.

  Yang S, Mi J, Liu Z, Wang B, Xia X, Wang R, Liu Y, Li Y. Yang S, et al. Molecules. 2017 Sep 26;22(10):1616. doi: 10.3390/molecules22101616. Molecules. 2017. PMID: 28954438 Free PMC article.

• Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.

  Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS. Aerts JM, et al. Diabetes. 2007 May;56(5):1341-9. doi: 10.2337/db06-1619. Epub 2007 Feb 7. Diabetes. 2007. PMID: 17287460 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database